BM histopathology combined with clinical data and molecular results were suggestive of CML chronic phase (CP) with concomitant JAK2 mutation and BCR::ABL1 rearrangement. This evidence concerns the gene JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive.